Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer

Summary

This phase II trial studies how well regorafenib and gemcitabine hydrochloride work as second-line therapy (treatment given when initial treatment doesn't work) in treating patients with pancreatic cancer that has spread to other parts of the body. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving regorafenib together with gemcitabine hydrochloride may kill more tumor cells.

Timeline

Start

2016-06-14

Primary completion

2017-09-01

Completion

2018-05-10

Outcome

Outcome not reported

Stopped (Enrollment): “PI discretion based on low accrual”

Drugs

Indications